id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S8652 R29100 |
Dean (Phenobarbital or Primidone), 2002 | Minor congenital malformations | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 3.80 [1.30;11.08] C | 23/63 5/38 | 28 | 63 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8672 R29211 |
Battino (Phenobarbital or Primidone) , 1992 | Minor anomalies | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 3.22 [0.18;58.97] C | 14/91 0/9 | 14 | 91 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8714 R29415 |
Van der Pol (Phenobarbital) (Controls unexposed, disease free), 1991 | Waldrop score >2 | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
4.50 [1.20;16.89] C excluded (control group) |
6/12 10/55 | 16 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8715 R29440 |
Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 | Waldrop score >2 | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.20 [0.29;4.91] C | 6/12 10/22 | 16 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8687 R29298 |
Robert (Phenobarbital), 1986 | Minor malformations | 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 0.86 [0.20;3.73] C | 4/40 4/35 | 8 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.93 [0.91;4.11] | 66 | 206 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital or Primidone; 2: Phenobarbital or Primidone; 3: Phenobarbital) (Controls unexposed, sick; 4: Phenobarbital;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 8714